> top > docs > PubMed:18657193 > annotations

PubMed:18657193 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T3 15-39 D002285 denotes ductal carcinoma in situ
T4 15-39 D002285 denotes ductal carcinoma in situ
T10 44-48 CVCL_5552 denotes DCIS
T9 44-48 D002285 denotes DCIS
T11 44-48 D002285 denotes DCIS
T12 57-63 UBERON:0000310 denotes breast
T14 112-116 CVCL_5552 denotes DCIS
T13 112-116 D002285 denotes DCIS
T15 112-116 D002285 denotes DCIS
T17 138-142 CVCL_5552 denotes DCIS
T16 138-142 D002285 denotes DCIS
T18 138-142 D002285 denotes DCIS
T20 162-170 CVCL_E722 denotes Kawasaki
T19 162-170 D009080 denotes Kawasaki
T21 162-170 D009080 denotes Kawasaki
T22 227-233 8164 denotes Suzuki
T25 327-351 D002285 denotes ductal carcinoma in situ
T26 327-351 D002285 denotes ductal carcinoma in situ
T32 356-360 CVCL_5552 denotes DCIS
T31 356-360 D002285 denotes DCIS
T33 356-360 D002285 denotes DCIS
T34 369-375 UBERON:0000310 denotes breast
T36 425-429 CVCL_5552 denotes DCIS
T35 425-429 D002285 denotes DCIS
T37 425-429 D002285 denotes DCIS
T39 451-455 CVCL_5552 denotes DCIS
T38 451-455 D002285 denotes DCIS
T40 451-455 D002285 denotes DCIS
T41 519-525 UBERON:0000310 denotes breast
T44 541-565 D002285 denotes ductal carcinoma in situ
T45 541-565 D002285 denotes ductal carcinoma in situ
T51 570-574 CVCL_5552 denotes DCIS
T50 570-574 D002285 denotes DCIS
T52 570-574 D002285 denotes DCIS
T54 582-586 CVCL_5552 denotes DCIS
T53 582-586 D002285 denotes DCIS
T55 582-586 D002285 denotes DCIS
T56 652-666 P04404 denotes chromogranin A
T57 652-666 P10354 denotes chromogranin A
T58 652-666 PR:000005421 denotes chromogranin A
T59 652-666 Q9XS63 denotes chromogranin A
T60 652-666 P33716 denotes chromogranin A
T61 652-666 P26339 denotes chromogranin A
T62 652-666 P05059 denotes chromogranin A
T63 652-666 P10645 denotes chromogranin A
T64 652-666 D053379 denotes chromogranin A
T65 674-687 P08247 denotes synaptophysin
T66 674-687 P20488 denotes synaptophysin
T68 674-687 PR:000015890 denotes synaptophysin
T69 674-687 Q5YJC1 denotes synaptophysin
T71 674-687 Q62277 denotes synaptophysin
T72 674-687 P07825 denotes synaptophysin
T67 674-687 D016708 denotes synaptophysin
T70 674-687 D016708 denotes synaptophysin
T74 696-700 CVCL_5552 denotes DCIS
T73 696-700 D002285 denotes DCIS
T75 696-700 D002285 denotes DCIS
T77 765-769 CVCL_5552 denotes DCIS
T76 765-769 D002285 denotes DCIS
T78 765-769 D002285 denotes DCIS
T79 779-782 1481724 denotes AND
T81 795-799 CVCL_5552 denotes DCIS
T80 795-799 D002285 denotes DCIS
T82 795-799 D002285 denotes DCIS
T84 826-830 CVCL_5552 denotes DCIS
T83 826-830 D002285 denotes DCIS
T85 826-830 D002285 denotes DCIS
T87 871-875 CVCL_5552 denotes DCIS
T86 871-875 D002285 denotes DCIS
T88 871-875 D002285 denotes DCIS
T90 902-906 CVCL_5552 denotes DCIS
T89 902-906 D002285 denotes DCIS
T91 902-906 D002285 denotes DCIS
T93 956-960 CVCL_5552 denotes DCIS
T92 956-960 D002285 denotes DCIS
T94 956-960 D002285 denotes DCIS
T95 974-980 UBERON:0002030 denotes nipple
T97 1051-1055 CVCL_5552 denotes DCIS
T96 1051-1055 D002285 denotes DCIS
T98 1051-1055 D002285 denotes DCIS
T99 1074-1083 D002277 denotes Carcinoma
T100 1074-1083 D002277 denotes Carcinoma
T102 1126-1130 CVCL_5552 denotes DCIS
T101 1126-1130 D002285 denotes DCIS
T103 1126-1130 D002285 denotes DCIS
T105 1149-1153 CVCL_5552 denotes DCIS
T104 1149-1153 D002285 denotes DCIS
T106 1149-1153 D002285 denotes DCIS
T108 1175-1179 CVCL_5552 denotes DCIS
T107 1175-1179 D002285 denotes DCIS
T109 1175-1179 D002285 denotes DCIS
T110 1280-1289 GO:0005737 denotes cytoplasm
T112 1317-1324 CVCL_E018 denotes spindle
T111 1317-1324 GO:0005819 denotes spindle
T113 1332-1338 CHEBI:33252 denotes nuclei
T114 1357-1373 UBERON:0002049 denotes vascular network
T116 1466-1470 CVCL_5552 denotes DCIS
T115 1466-1470 D002285 denotes DCIS
T117 1466-1470 D002285 denotes DCIS
T119 1487-1491 CVCL_5552 denotes DCIS
T118 1487-1491 D002285 denotes DCIS
T120 1487-1491 D002285 denotes DCIS
T124 1513-1516 CHEBI:61987 denotes MIB
T129 1513-1518 PR:Q804S5 denotes MIB-1
T130 1513-1518 PR:Q80SY4 denotes MIB-1
T131 1513-1518 PR:Q9VUX2 denotes MIB-1
T132 1513-1518 PR:000010396 denotes MIB-1
T133 1513-1518 PR:Q86YT6 denotes MIB-1
T135 1550-1554 CVCL_5552 denotes DCIS
T134 1550-1554 D002285 denotes DCIS
T136 1550-1554 D002285 denotes DCIS
T138 1574-1578 CVCL_5552 denotes DCIS
T137 1574-1578 D002285 denotes DCIS
T139 1574-1578 D002285 denotes DCIS
T141 1607-1611 CVCL_5552 denotes DCIS
T140 1607-1611 D002285 denotes DCIS
T142 1607-1611 D002285 denotes DCIS
T143 1643-1652 CHEBI:50114 denotes oestrogen
T145 1657-1669 8727 denotes progesterone
T148 1657-1678 Q9GLW0 denotes progesterone receptor
T149 1657-1678 A7XW16 denotes progesterone receptor
T150 1657-1678 A7X8C2 denotes progesterone receptor
T151 1657-1678 Q00175 denotes progesterone receptor
T152 1657-1678 A7X8B5 denotes progesterone receptor
T153 1657-1678 Q8AYI2 denotes progesterone receptor
T154 1657-1678 A7X8C7 denotes progesterone receptor
T155 1657-1678 Q63449 denotes progesterone receptor
T156 1657-1678 A7X8C9 denotes progesterone receptor
T157 1657-1678 Q28590 denotes progesterone receptor
T158 1657-1678 A7X8B9 denotes progesterone receptor
T159 1657-1678 A7X8D4 denotes progesterone receptor
T160 1657-1678 A7X8B3 denotes progesterone receptor
T161 1657-1678 P07812 denotes progesterone receptor
T162 1657-1678 A7XW20 denotes progesterone receptor
T163 1657-1678 A7X8B7 denotes progesterone receptor
T164 1657-1678 A7XW25 denotes progesterone receptor
T165 1657-1678 P06401 denotes progesterone receptor
T166 1657-1678 PR:000012621 denotes progesterone receptor
T167 1657-1678 P79373 denotes progesterone receptor
T168 1657-1678 P06186 denotes progesterone receptor
T169 1657-1678 A7X8C4 denotes progesterone receptor
T171 1657-1678 A7X8D2 denotes progesterone receptor
T170 1657-1678 D011980 denotes progesterone receptor
T172 1689-1692 CVCL_1K15 denotes HER
T173 1689-1693 PR:P04626 denotes HER2
T174 1689-1693 PR:000002082 denotes HER2
T175 1689-1693 PR:Q03557 denotes HER2
T176 1689-1693 PR:P34708 denotes HER2
T177 1689-1693 PR:Q5AK64 denotes HER2
T179 1713-1717 CVCL_5552 denotes DCIS
T178 1713-1717 D002285 denotes DCIS
T180 1713-1717 D002285 denotes DCIS
T182 1752-1756 CVCL_5552 denotes DCIS
T181 1752-1756 D002285 denotes DCIS
T183 1752-1756 D002285 denotes DCIS
T184 1851-1858 SO:0001147 denotes variant
T186 1862-1866 CVCL_5552 denotes DCIS
T185 1862-1866 D002285 denotes DCIS
T187 1862-1866 D002285 denotes DCIS

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-149 DRI_Background denotes Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast--comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases.
T2 162-581 DRI_Approach denotes Kawasaki T, Nakamura S, Sakamoto G, Murata S, Tsunoda-shimizu H, Suzuki K, Takahashi O, Nakazawa T, Kondo T & Katoh R (2008) Histopathology53, 288-298Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast - comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases Aims: To clarify the clinicopathological significance of breast neuroendocrine ductal carcinoma in situ (NE-DCIS), i.e.
T3 582-770 DRI_Background denotes DCIS in which >50% of cells immunohistochemically express NE markers (chromogranin A and/or synaptophysin), 20 NE-DCIS were studied and the findings compared with those of 274 non-NE-DCIS.
T4 780-831 DRI_Unspecified denotes ND RESULTS: NE-DCIS accounted for 6.8% of all DCIS.
T5 832-918 DRI_Background denotes Mean patient age was 50.4 years for NE-DCIS and 49.6 years for non-NE-DCIS (P = 0.66).
T6 919-1073 DRI_Outcome denotes The main clinical presentation of NE-DCIS was a bloody nipple discharge, seen in 72%, significantly different from the 5% in non-NE-DCIS cases (P < 0.01).
T7 1074-1171 DRI_Background denotes Carcinoma was preoperatively diagnosed in 67% of NE-DCIS and 95% of non-NE-DCIS cases (P < 0.01).
T8 1172-1339 DRI_Background denotes NE-DCIS was histologically characterized by a predominantly solid growth of cancer cells with fine-granular cytoplasm and ovoid, or occasionally spindle-shaped nuclei.
T9 1340-1390 DRI_Background denotes A well-developed vascular network was also common.
T10 1391-1503 DRI_Approach denotes Nuclear grades and Van Nuys classification were significantly lower for NE-DCIS than for non-NE-DCIS (P < 0.01).
T11 1504-1590 DRI_Approach denotes The mean MIB-1 labelling index was 4.3% in NE-DCIS and 8.1% in non-NE-DCIS (P < 0.01).
T12 1591-1735 DRI_Outcome denotes Furthermore, NE-DCIS cases had significantly higher oestrogen and progesterone receptor and lower HER2 scores than non-NE-DCIS cases (P < 0.01).
T13 1749-1867 DRI_Background denotes NE-DCIS has characteristic clinicopathological features and can, therefore, be regarded as a distinct variant of DCIS.

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 162-770 UNLABELLED denotes Kawasaki T, Nakamura S, Sakamoto G, Murata S, Tsunoda-shimizu H, Suzuki K, Takahashi O, Nakazawa T, Kondo T & Katoh R (2008) Histopathology53, 288-298Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast - comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases Aims: To clarify the clinicopathological significance of breast neuroendocrine ductal carcinoma in situ (NE-DCIS), i.e. DCIS in which >50% of cells immunohistochemically express NE markers (chromogranin A and/or synaptophysin), 20 NE-DCIS were studied and the findings compared with those of 274 non-NE-DCIS.
T2 792-1735 RESULTS denotes NE-DCIS accounted for 6.8% of all DCIS. Mean patient age was 50.4 years for NE-DCIS and 49.6 years for non-NE-DCIS (P = 0.66). The main clinical presentation of NE-DCIS was a bloody nipple discharge, seen in 72%, significantly different from the 5% in non-NE-DCIS cases (P < 0.01). Carcinoma was preoperatively diagnosed in 67% of NE-DCIS and 95% of non-NE-DCIS cases (P < 0.01). NE-DCIS was histologically characterized by a predominantly solid growth of cancer cells with fine-granular cytoplasm and ovoid, or occasionally spindle-shaped nuclei. A well-developed vascular network was also common. Nuclear grades and Van Nuys classification were significantly lower for NE-DCIS than for non-NE-DCIS (P < 0.01). The mean MIB-1 labelling index was 4.3% in NE-DCIS and 8.1% in non-NE-DCIS (P < 0.01). Furthermore, NE-DCIS cases had significantly higher oestrogen and progesterone receptor and lower HER2 scores than non-NE-DCIS cases (P < 0.01).
T3 1749-1867 CONCLUSIONS denotes NE-DCIS has characteristic clinicopathological features and can, therefore, be regarded as a distinct variant of DCIS.